2015 Next Generation Dx Summit

Cambridge Healthtech Institute’s Second Annual
Clinical Application of Cell-Free DNA
Enabling Non-Invasive Diagnostics
August 19-20, 2015 | Capital Hilton | Washington, DC


Cell-free DNA (cfDNA) is a relatively new technique with an exponential increase in applications for a variety of uses. The clinical utility of these new methods will be evaluated by thought-leaders in the field using the latest case studies. Non-invasive detection of cell-free DNA promises to impact clinical protocols and treatment regimens. cfDNA will determine the standard of care in oncology, transplant medicine and cardiovascular disease. This field is emerging as one of the most promising and exciting areas of medicine and has already made a huge impact on prenatal care.

Preliminary Agenda

KEYNOTE PRESENTATION: Monitoring the Cancer Genome in Plasma Using Circulating Tumor DNA

Nitzan Rosenfeld, Ph.D., Senior Group Leader, CRUK-CI, University of Cambridge; CSO, Inivata, Ltd.


NOVEL CLINICAL APPLICATIONS OF RARE MUTATION DETECTION TECHNOLOGY 

PAP Smear Diagnostics for Endometrial and Ovarian Cancers

Luis A. Diaz, M.D., Associate Professor, Oncology, Johns Hopkins Sidney Kimmel Comprehensive Cancer Center

Cell-Free DNA in Transplant Medicine

Kiran K. Khush, M.D., MAS, Assistant Professor, Medicine, Cardiovascular Medicine, Stanford University

Clonal Hematopoiesis and Blood-Cancer Risk Inferred from Exome Sequencing of Blood-Derived DNA

Giulio Genovese, Ph.D., Computational Biologist, Stanley Center for Psychiatric Research, Broad Institute


TECHNOLOGY FOR PROFILING cfDNA 

Whole Genome Sequencing of Plasma DNA in Patients with Cancer

Michael R. Speicher, M.D., Professor and Chairman, Institute of Human Genetics, Medical University of Graz

Diagnostic Applications of Cell-Free DNA in Solid Organ and Bone Marrow Transplantation

Iwijn De Vlaminck, Ph.D., Assistant Professor, Biomedical Engineering, Cornell University

TransgenomicThe Use of Multiplexed ICE COLD-PCR coupled to Multiple Downstream Analysis Platforms for Detection of Low Level Sequence Alterations

Katherine Richardson, Ph.D., Vice President, Research & Development, Transgenomic, Inc. 


CLINICAL APPLICATIONS IN ONCOLOGY 

An Ultrasensitive Method for Quantitating Circulating Tumor DNA with Broad Patient Coverage

Maximilian Diehn, M.D., Ph.D., Assistant Professor, Radiation Oncology, Stanford Cancer Institute, Institute for Stem Cell Biology & Regenerative Medicine, Stanford University

Multi-Marker Analysis of Circulating Cell-Free DNA toward Personalized Medicine for Colorectal Cancer

Alain R. Thierry, Ph.D., Senior Investigator, Research Institute in Oncology of Montpellier, INSERM

Circulating Plasma Tumor DNA as a Biomarker for Individualized Medicine in Early Stage Breast Cancer

Ben H. Park, M.D., Ph.D., Associate Professor, Oncology, Johns Hopkins University

Circulating Tumor DNA as a Non-Invasive Substitute to Metastasis Biopsy for Tumor Genotyping and Personalized Medicine in a Prospective Trial across All Tumor Types

Jean-Yves Pierga, M.D., Ph.D., Professor, Circulating Cancer Biomarkers Lab, SiRIC, Translational Research, Institut Curie



For more details on the conference, please contact:
Christina Lingham
Executive Director, Conferences
Cambridge Healthtech Institute
T: (+1) 781-972-5464
E: clingham@healthtech.com 

For exhibit & sponsorship opportunities, please contact:
Joseph Vacca
Associate Director, Business Development
Cambridge Healthtech Institute
T: (+1) 781-972-5431
E: jvacca@healthtech.com 

Japan-Flag Korea-Flag China-Simplified-Flag China-Traditional-Flag 

2014 Brochure

2014 Brochure 


Premier Sponsor

ThermoFisher Scientific logo 


Related Products

MDX_Logo_150x150